Multifunctional Antibody Agonists Targeting Glucagon‐like Peptide‐1, Glucagon, and Glucose‐Dependent Insulinotropic Polypeptide Receptors
Lists
Only you see this
Abstract
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor (GLP‐1R), glucagon (GCG) receptor (GCGR), and glucose‐dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide) receptor (GIPR), are three metabolically related peptide hormone receptors. A novel approach to the generation of multifunctional antibody agonists that activate these receptors has been developed. Native or engineered peptide agonists for GLP‐1R, GCGR, and GIPR were fused to the N‐terminus of the heavy chain or light chain of an antibody, either alone or in pairwise combinations. The fusion proteins have similar in vitro biological activities on the cognate receptors as the corresponding peptides, but circa 100‐fold longer plasma half‐lives. The GLP‐1R mono agonist and GLP‐1R/GCGR dual agonist antibodies both exhibit potent effects on glucose control and body weight reduction in mice, with the dual agonist antibody showing enhanced activity in the latter.
BibTeX
@inproceedings{wang2016multifunctional,
author = {Ying Wang and Jintang Du and Huafei Zou and Yan Liu and Yuhan Zhang and J. González and Elizabeth Chao and Lucy Lu and Pengyu Yang and Holly Parker and Vân Nguyên-Trân and Weijun Shen and Danling Wang and Peter G. Schultz and Feng Wang},
title = {{Multifunctional Antibody Agonists Targeting Glucagon‐like Peptide‐1, Glucagon, and Glucose‐Dependent Insulinotropic Polypeptide Receptors}},
booktitle = {Angewandte},
year = {2016},
doi = {10.1002/ange.201606321},
}Loading related content...